IMTIB   27019
INSTITUTO DE MEDICINA TRASLACIONAL E INGENIERIA BIOMEDICA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Gut metatranscriptomics and metabolomics reveal association of cysteine and purine metabolisms with metabolic associated fatty liver disease (MAFLD
Autor/es:
FLAVIA MAZZINI; SHILPA PANDIT ; FRANK COOK; HADDAD L; ADRIAN NARVAEZ; GUTT, SUSANA; MARRO, MARTIN L.; MASCARDI MF; LEANDRA MANSUR; JOHN GOUNARIDES; TAMAROFF, ANA JESICA; ANDERS, MARGARITA; GADANO A ; ALBERTO PENAS STEINHARDT; VERA RUDA; YANQUN WANG; MARCIANO S; CASCIATO, PAOLA; ORLANDO NICOLAS FEDERICO OROZCO GANEM; CELIA MENDEZ GARCIA; J. TRINKS
Reunión:
Congreso; XXVI Congreso de la Asociación Latinoamericana de Enfermedades del Hígado (ALEH) 2021; 2021
Institución organizadora:
Asociación Latinoamericana de Enfermedades del Hígado (ALEH)
Resumen:
BACKGROUND: The gut microbiome represents a niche for biomarkers discovery to risk-stratifyMAFLD patients. However, each population may have unique microbiome signatures and studies are needed in Latin America where MAFLD prevalence and severity are high.AIMS: To identify gut metatranscriptome and metabolome signatures associated with MAFLD andsteatohepatitis (SH) in Argentina.METHODS: Stool samples, diet, demographic and clinical data were obtained from 33 biopsy-provenpatients (12 simple steatosis -SS- and 21 SH) and 19 healthy volunteers (HV). PNPLA3 rs738409 SNP was genotyped. HPLC, flow injection analysis with MS/MS in tandem and MetaboAnalyst-v4.0 wereused for metabolomics. RNA-seq was performed in NovaSeq6000®. bioBakery-v1.8 and Maaslin2-v1.2.0 were used for data analysis.RESULTS: BMI was higher in MAFLD patients, particularly in SH (q=4.49e-06). After adjusting for BMI, 89 and 53 gene family clusters were differentially expressed between HV and MAFLD and between SS and SH, respectively (q